Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone734-845-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$290,000.00
Profitability
Miscellaneous
Employees32
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions
What is Millendo Therapeutics' stock symbol?
Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."
How were Millendo Therapeutics' earnings last quarter?
Millendo Therapeutics Inc (NASDAQ:MLND) issued its earnings results on Monday, August, 12th. The company reported ($0.74) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.81) by $0.07. View Millendo Therapeutics' Earnings History.
When is Millendo Therapeutics' next earnings date?
What price target have analysts set for MLND?
7 Wall Street analysts have issued 1 year price objectives for Millendo Therapeutics' shares. Their forecasts range from $22.00 to $29.00. On average, they expect Millendo Therapeutics' share price to reach $25.1429 in the next year. This suggests a possible upside of 275.3% from the stock's current price. View Analyst Price Targets for Millendo Therapeutics.
What is the consensus analysts' recommendation for Millendo Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Millendo Therapeutics.
Has Millendo Therapeutics been receiving favorable news coverage?
Media headlines about MLND stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Millendo Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Millendo Therapeutics.
Who are some of Millendo Therapeutics' key competitors?
Some companies that are related to Millendo Therapeutics include Theratechnologies (THERF), Prothena (PRTA), Cyclerion Therapeutics (CYCN), DURECT (DRRX), Forty Seven (FTSV), Kindred Biosciences (KIN), Albireo Pharma (ALBO), BIOFRONTERA AG/ADR (BFRA), Minerva Neurosciences (NERV), Avid Bioservices (CDMO), CV Sciences (CVSI), Clovis Oncology (CLVS), OvaScience (OVAS), Geron (GERN) and Assembly Biosciences (ASMB).
What other stocks do shareholders of Millendo Therapeutics own?
Who are Millendo Therapeutics' key executives?
Millendo Therapeutics' management team includes the folowing people:
- Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 45)
- Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
- Mr. Louis J. Arcudi III, MBA, Chief Financial Officer (Age 58)
- Mr. Jeffery M. Brinza J.D., Chief Admin. Officer, Gen. Counsel & Sec. (Age 57)
- Dr. Pharis Mohideen, Chief Medical Officer (Age 54)
Who are Millendo Therapeutics' major shareholders?
Millendo Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.50%), Vanguard Group Inc. (2.47%), Renaissance Technologies LLC (1.56%), International Biotechnology Trust PLC (1.33%), AWM Investment Company Inc. (0.58%) and Northern Trust Corp (0.31%).
Which institutional investors are buying Millendo Therapeutics stock?
MLND stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., International Biotechnology Trust PLC, Renaissance Technologies LLC, AWM Investment Company Inc., Northern Trust Corp, Charles Schwab Investment Management Inc. and Bank of New York Mellon Corp.
How do I buy shares of Millendo Therapeutics?
Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Millendo Therapeutics' stock price today?
One share of MLND stock can currently be purchased for approximately $6.70.
How big of a company is Millendo Therapeutics?
Millendo Therapeutics has a market capitalization of $89.86 million and generates $290,000.00 in revenue each year. The company earns $-27,190,000.00 in net income (profit) each year or ($17.58) on an earnings per share basis. Millendo Therapeutics employs 32 workers across the globe.View Additional Information About Millendo Therapeutics.
What is Millendo Therapeutics' official website?
How can I contact Millendo Therapeutics?
Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MA, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]
MarketBeat Community Rating for Millendo Therapeutics (NASDAQ MLND)
MarketBeat's community ratings are surveys of what our community members think about Millendo Therapeutics and other stocks. Vote "Outperform" if you believe MLND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLND will underperform the S&P 500 over the long term. You may vote once every thirty days.
